AcelRx Pharmaceuticals Stock News

Merger activity increased last week with one new deal announced. The acquisition of Tetraphase Pharmaceuticals by Melinta Therapeutics for $55 million. Yatra On

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * BioMari

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (...

AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settin

REDWOOD CITY, Calif., June 1, 2020 /PRNewswire via COMTEX/ -- REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),...

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, t

Merger activity ground to a halt last week with no new deals announced. Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals enter into a second amendment. Tex

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settin